2021 “Concrete in Life” Global Photography Competition Launches – Focus on Sustainability, Beauty and Versatility of Concrete
23.8.2021 14:00:00 EEST | Business Wire | Press release
The third annual GCCA “Concrete in Life” photography competition has today launched with a call for amateur and professional photographers from around the world to capture the role of concrete in their lives and its role in the sustainable world of tomorrow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005132/en/
Concrete in Life 2020 competition winner - Nurlan Tahirli (Photo: Business Wire)
Concrete plays a key role in supporting society around the world. Its durability, strength, resilience and boundless versatility means it can be used for nearly any application, while its properties such as thermal mass, recyclability and carbon uptake make it the most sustainable building material.
Judges include Isabel Allen, Editor at Architecture Today, Gian Luca Barone from Zaha Hadid Architects and experts from the Global Cement and Concrete Association (GCCA). They will be looking for entries showing concrete contributing to their individual lives and wider society, and notably sustainable buildings and infrastructure, to inspire the public in the run up to COP26, as the GCCA prepares to announce its detailed roadmap to zero carbon concrete.
Contestants are invited to capture imagery in the following categories, which include a brand new Sustainable Concrete category:
- Urban design and use – images of the city landscapes and buildings around us, both well-known and hidden away
- Infrastructure – photographs of our infrastructure, in our cities and rural, above and below ground
- Concrete in daily life – the human side of concrete and how it’s used and interacted with daily
- Sustainable Concrete – how concrete is used in sustainable construction, buildings and infrastructure such as wind farms, dams, green overpasses, wildlife crossings, green buildings
The competition crown one winner for the professional and amateur brackets of each category as well as one overall winner for the “Best Concrete in Life” photo of the year from the eight finalists. Each category winner will receive $2,500 in prize money, while the overall winner will receive $10,000.
Thomas Guillot, GCCA Chief Executive, said: “Being the world’s most used human-made product, concrete provides the foundation for so many lives. The competition is designed to capture that importance and demonstrate its versatility throughout society. Entries to the first two ‘Concrete in Life’ competitions from both professionals and amateurs were exceptional and managed to capture concrete’s strength, durability and resilience, and we’re so excited to be launching the third annual competition. We look forward to receiving a wide array of unique and inspiring entries from all over the world.”
The annual competition by the GCCA attracts tens of thousands of entries from professional and amateur photographers and challenges participants to capture photos that highlight the beauty of concrete and the vital role it plays in our society.
To enter the competition, participants should post a picture that they’ve taken on Instagram or Twitter using the hashtags #ConcreteInLife2021, #UrbanConcrete, #ConcreteInfrastructure, #ConcreteInDailyLife, and #SustainableConcrete. They should also tag the GCCA – @the.gcca on Instagram or @theGCCA on Twitter.
Winners will also be invited to speak about their images with the GCCA, with their images shared on GCCA’s website and social media channels.
Judging the entries are:
- Gian Luca Barone, Senior Associate, Zaha Hadid Architects
- John Fairley, Design Director, Curious Productions
- Thomas Guillot, GCCA Chief Executive
- Isabel Allen, Editor, Architecture Today
The competition will run until October 22nd 2021, with the winners announced during January 2022. Full competition details can be found at https://gccassociation.org/concreteinlife2021/
-ends-
About the GCCA:
Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210823005132/en/
Contact information
Media enquiries should be directed to:
Matt Peacock, BCW
GCCA@BCW-global.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
